Inger Johansson

Publications
Grants
Public outreach and news

Articles

Journal article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2024;80(10):1531-1541
Impact of CYP2D6*2, CYP2D6*35, rs5758550, and related haplotypes on risperidone clearance in vivo
Storset E; Braten LS; Ingelman-Sundberg M; Johansson I; Molden E; Kringen MK
Article: LANCET. 2023;401(10374):347-356
A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study
Swen JJ; van der Wouden CH; Manson LEN; Abdullah-Koolmees H; Blagec K; Blagus T; Boehringer S; Cambon-Thomsen A; Cecchin E; Cheung K-C; Deneer VHM; Dupui M; Ingelman-Sundberg M; Jonsson S; Joefield-Roka C; Just KS; Karlsson MO; Konta L; Koopmann R; Kriek M; Lehr T; Mitropoulou C; Rial-Sebbag E; Rollinson V; Roncato R; Samwald M; Schaeffeler E; Skokou M; Schwab M; Steinberger D; Stingl JC; Tremmel R; Turner RM; van Rhenen MH; Fajardo CLD; Dolzan V; Patrinos GP; Pirmohamed M; Sunder-Plassmann G; Toffoli G; Guchelaar H-J
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;112(5):1000-1003
Liquid Biopsies or Therapeutic Drug Monitoring for CYP Activity Profile Determination
Pridgeon CS; Johansson I; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;111(5):1165-1174
The Polymorphic Nuclear Factor NFIB Regulates Hepatic CYP2D6 Expression and Influences Risperidone Metabolism in Psychiatric Patients
Lenk HC; Kloditz K; Johansson I; Smith RL; Jukic M; Molden E; Ingelman-Sundberg M
Article: SCIENCE TRANSLATIONAL MEDICINE. 2021;13(603):eabf3637
Toward predicting CYP2D6-mediated variable drug response from CYP2D6 gene sequencing data
van der Lee M; Allard WG; Vossen RHAM; Baak-Pablo RF; Menafra R; Deiman BALM; Deenen MJ; Neven P; Johansson I; Gastaldello S; Ingelman-Sundberg M; Guchelaar H-J; Swen JJ; Anvar SY
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2020;108(4):844-855
Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling A; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Article: CELLS. 2020;9(4):E964-964
Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Hurrell T; Kastrinou-Lampou V; Fardellas A; Hendriks DFG; Nordling A; Johansson I; Baze A; Parmentier C; Richert L; Ingelman-Sundberg M
Article: SCIENTIFIC REPORTS. 2018;8(1):14297
Human hepatic 3D spheroids as a model for steatosis and insulin resistance
Kozyra M; Johansson I; Nordling A; Ullah S; Lauschke VM; Ingelman-Sundberg M
Article: HEPATOLOGY. 2016;64(5):1743-1756
Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation
Lauschke VM; Vorrink SU; Moro SML; Rezayee F; Nordling A; Hendriks DFG; Bell CC; Sison-Young R; Park BK; Goldring CE; Ellis E; Johansson I; Mkrtchian S; Andersson TB; Ingelman-Sundberg M
Article: FEBS LETTERS. 2016;590(3):330-339
Membrane topology and search for potential redox partners of colon cancer-specific cytochrome P450 2W1
Guo J; Thiess S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Article: STEM CELLS INTERNATIONAL. 2016;2016:2475631
High Content Analysis of Human Pluripotent Stem Cell Derived Hepatocytes Reveals Drug Induced Steatosis and Phospholipidosis
Pradip A; Steel D; Jacobsson S; Holmgren G; Ingelman-Sundberg M; Sartipy P; Bjorquist P; Johansson I; Edsbagge J
Article: PLOS ONE. 2016;11(9):e0162379
Human Cytochrome P450 2W1 Is Not Expressed in Adrenal Cortex and Is Only Rarely Expressed in Adrenocortical Carcinomas
Nole P; Duijndam B; Stenman A; Juhlin CC; Kozyra M; Larsson C; Ingelman-Sundberg M; Johansson I
Article: CLINICAL CANCER RESEARCH. 2015;21(2):322-328
Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy
Apellaniz-Ruiz M; Lee M-Y; Sanchez-Barroso L; Gutierrez-Gutierrez G; Calvo I; Garcia-Estevez L; Sereno M; Garcia-Donas J; Castelo B; Guerra E; Leandro-Garcia LJ; Cascon A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodriguez-Antona C
Article: PLOS ONE. 2015;10(4):e0122820
Developmental Regulation and Induction of Cytochrome P450 2W1, an Enzyme Expressed in Colon Tumors
Choong E; Guo J; Persson A; Virding S; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Article: PHARMACOGENOMICS. 2015;16(9):929-937
Role of cytochrome P450 2C8*3 (CYP2C8*3) in paclitaxel metabolism and paclitaxel-induced neurotoxicity
Lee M-Y; Apellaniz-Ruiz M; Johansson I; Vikingsson S; Bergmann TK; Brosen K; Green H; Rodriguez-Antona C; Ingelman-Sundberg M
Article: PHARMACOGENOMICS JOURNAL. 2014;14(4):343-349
High warfarin sensitivity in carriers of CYP2C9*35 is determined by the impaired interaction with P450 oxidoreductase
Lee M-Y; Borgiani P; Johansson I; Oteri F; Mkrtchian S; Falconi M; Ingelman-Sundberg M
Article: ACTA ONCOLOGICA. 2014;53(7):885-891
The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases
Stenstedt K; Hallstrom M; Ledel F; Ragnhammar P; Ingelman-Sundberg M; Johansson I; Edler D
Article: PHARMACOGENOMICS. 2013;14(13):1615-1622
CYP2W1 polymorphism: functional aspects and relation to risk for colorectal cancer
Stenstedt K; Travica S; Guo J; Barragan I; Pors K; Patterson L; Edler D; Mkrtchian S; Johansson I; Ingelman-Sundberg M
Article: JOURNAL OF MEDICINAL CHEMISTRY. 2013;56(15):6273-6277
Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity
Sheldrake HM; Travica S; Johansson I; Loadman PM; Sutherland M; Elsalem L; Illingworth N; Cresswell AJ; Reuillon T; Shnyder SD; Mkrtchian S; Searcey M; Ingelman-Sundberg M; Patterson LH; Porst K
Article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 2013;113(2):126-131
Sex Difference in Formation of Propofol Metabolites: A Replication Study
Choong E; Loryan I; Lindqvist M; Nordling A; el Bouazzaoui S; van Schaik RH; Johansson I; Jakobsson J; Ingelman-Sundberg M
Article: CLINICAL CANCER RESEARCH. 2013;19(11):2952-2961
Colon Cancer-Specific Cytochrome P450 2W1 Converts Duocarmycin Analogues into Potent Tumor Cytotoxins
Travica S; Pors K; Loadman PM; Shnyder SD; Johansson I; Alandas MN; Sheldrake HM; Mkrtchian S; Patterson LH; Ingelman-Sundberg M
Journal article: CANCER RESEARCH. 2013;73(8_Supplement):2224
Abstract 2224: Re-engineering of the duocarmycin structural architecture enables tumour-selective CYP2W1-mediated drug activation in human colon cancer xenografts.
Pors K; Travica S; Loadman PM; Shnyder SD; Sutherland M; Sheldrake HM; Searcey M; Johansson I; Mkrtchian S; IngelmanSundberg M; Patterson LH
Article: ANTICANCER RESEARCH. 2012;32(9):3869-3874
The Expression of CYP2W1: A Prognostic Marker in Colon Cancer
Stenstedt K; Hallstrom M; Johansson I; Ingelman-Sundberg M; Ragnhammar P; Edler D
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2012;68(4):397-406
Influence of sex on propofol metabolism, a pilot study: implications for propofol anesthesia
Loryan I; Lindqvist M; Johansson I; Hiratsuka M; van der Heiden I; van Schaik RHN; Jakobsson J; Ingelman-Sundberg M
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(9):6307-6317
Amidoxime Reductase System Containing Cytochrome b₅ Type B (CYB5B) and MOSC2 Is of Importance for Lipid Synthesis in Adipocyte Mitochondria
Neve EPA; Nordling A; Andersson TB; Hellman U; Diczfalusy U; Johansson I; Ingelman-Sundberg M
Article: ATLA-ALTERNATIVES TO LABORATORY ANIMALS. 2011;39(2):147-171
Toward Preclinical Predictive Drug Testing for Metabolism and Hepatotoxicity by Using In Vitro Models Derived from Human Embryonic Stem Cells and Human Cell Lines - A Report on the Vitrocellomics EU-project
Mandenius C-F; Andersson TB; Alves PM; Batzl-Hartmann C; Bjorquist P; Carrondo MJT; Chesne C; Coecke S; Edsbagge J; Fredriksson JM; Gerlach JC; Heinzle E; Ingelman-Sundberg M; Johansson I; Kuppers-Munther B; Mueller-Vieira U; Noor F; Zeilinger K
Article: TOXICOLOGICAL SCIENCES. 2011;120(1):1-13
Genetic Polymorphism and Toxicology-With Emphasis on Cytochrome P450
Johansson I; Ingelman-Sundberg M
Article: MOLECULAR PHARMACOLOGY. 2010;78(6):1004-1011
Colorectal Cancer-Specific Cytochrome P450 2W1: Intracellular Localization, Glycosylation, and Catalytic Activity
Gomez A; Nekvindova J; Travica S; Lee M-Y; Johansson I; Edler D; Mkrtchian S; Ingelman-Sundberg M
Article: JOURNAL OF BIOTECHNOLOGY. 2010;145(3):284-294
Hepatocyte-like cells derived from human embryonic stem cells specifically via definitive endoderm and a progenitor stage
Brolen G; Sivertsson L; Bjorquist P; Eriksson G; Ek M; Semb H; Johansson I; Andersson TB; Ingelman-Sundberg M; Heins N
Article: JOURNAL OF HEPATOLOGY. 2009;50(3):572-583
The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model
Butura A; Nilsson K; Morgan K; Morgan TR; French SW; Johansson I; Schuppe-Koistinen I; Ingelman-Sundberg M
Article: CYTOGENETIC AND GENOME RESEARCH. 2008;123(1-4):195-204
CNVs of human genes and their implication in pharmacogenetics
Johansson I; Ingelman-Sundberg M
Article: BIOCHEMICAL PHARMACOLOGY. 2007;74(3):496-503
Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells
Ek M; Soderdahl T; Kuppers-Munther B; Edsbagge J; Andersson TB; Bjorquist P; Cotgreave I; Jernstrom B; Ingelman-Sundberg M; Johansson I
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2006;341(2):451-458
Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1
Karlgren M; Gomez A; Stark K; Svärd J; Rodriguez-Antona C; Oliw E; Bernal ML; Cajal SRY; Johansson I; Ingelman-Sundberg M
Article: ATHEROSCLEROSIS. 2005;182(1):37-45
Common polymorphisms in the CYP7A1 gene do not contribute to variation in rates of bile acid synthesis and plasma LDL cholesterol concentration
Abrahamsson A; Krapivner S; Gustafsson U; Muhrbeck O; Eggertsen G; Johansson I; Persson I; Angelin B; Ingelman-Sundberg M; Björkhem I; Einarsson C; van't Hooft FM
Article: DRUG METABOLISM AND DISPOSITION. 2005;33(4):570-578
Characterization and partial purification of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime
Andersson S; Hofmann Y; Nordling Å; Li XQ; Nivelius S; Andersson TB; Ingelman-Sundberg M; Johansson I
Article: BIOCHEMICAL PHARMACOLOGY. 2004;67(7):1249-1258
Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling
Butura A; Johansson I; Nilsson K; Wärngård L; Ingelman-Sundberg M; Schuppe-Koistinen I
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2004;315(3):679-685
Characterization and tissue distribution of a novel human cytochrome P450 - CYP2U1
Karlgren M; Backlund M; Johansson I; Oscarson M; Ingelman-Sundberg M
Article: DRUG METABOLISM AND DISPOSITION. 2003;31(6):755-761
Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism
Westlind-Johnsson A; Malmebo S; Johansson A; Otter C; Andersson TB; Johansson I; Edwards RJ; Boobis AR; Ingelman-Sundberg M
Journal article: MOLECULAR DIAGNOSIS & THERAPY. 2003;3(5):355-358
Cytochrome P450 2J2 polymorphism in healthy Caucasians and those with diabetes mellitus.
Pucci L; Lucchesi D; Chirulli V; Penno G; Johansson I; Gervasi P; Del Prato S; Longo V
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2002;58(1):19-27
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis
Thapar MM; Ashton M; Lindegårdh N; Bergqvist Y; Nivelius S; Johansson I; Björkman A
Article: PHARMACOGENETICS AND GENOMICS. 2001;11(5):417-427
Characterization of the CYP2D6*29 allele commonly present in a blade Tanzanian population causing reduced catalytic activity
Wennerholm A; Johansson I; Hidestrand M; Bertilsson L; Gustafsson LL; Ingelman-Sundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 2000;56(9-10):679-683
CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients
Scordo MG; Spina E; Romeo P; Dahl ML; Bertilsson L; Johansson I; Sjöqvist F
Article: PSYCHOPHARMACOLOGY. 1999;147(3):300-305
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
Scordo MG; Spina E; Facciolà G; Avenoso A; Johansson I; Dahl ML
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(6):707-714
Decreased capacity for debrisoquine metabolism among black Tanzanians:: analyses of the CYP2D6 genotype and phenotype
Wennerholm A; Johansson I; Massele AY; Jande M; Alm C; Aden-Abdi Y; Dahl ML; Ingelman-Sundberg M; Bertilsson L; Gustafsson LL
Article: PHARMACOGENETICS AND GENOMICS. 1999;9(5):657-660
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl ML; Ingelman-Sundberg M; Bertilsson L
Journal article: PHARMACOGENETICS AND GENOMICS. 1999;9(5):657
Ten percent of North Spanish individuals carry duplicated or triplicated CYP2D6 genes associated with ultrarapid metabolism of debrisoquine
Bernal ML; Sinues B; Johansson I; McLellan RA; Wennerholm A; Dahl M-L; Ingelman-Sundberg M; Bertilsson L
Article: INTERNATIONAL JOURNAL OF CANCER. 1999;81(3):325-329
Genetic polymorphism of xenobiotic metabolizing enzymes among Chinese lung cancer patients
Persson I; Johansson I; Lou YC; Yue QY; Duan LS; Bertilsson L; Ingelman-Sundberg M
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;258(1):227
Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population (vol 254, pg 628, 1999)
Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;254(3):628-631
Validation of methods for CYP2C9 genotyping:: Frequencies of mutant alleles in a Swedish population
Yasar Ü; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjoqvist F
Article: GENE. 1999;226(2):327-338
Genetic mechanisms for duplication and multiduplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes
Lundqvist E; Johansson I; Ingelman-Sundberg M
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1998;64(4):391-401
Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Article: PHARMACOGENETICS AND GENOMICS. 1998;8(2):119-123
Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction
Bathum L; Johansson I; Ingelman-Sundberg M; Horder M; Brosen K
Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1997;272(50):31755-31763
Signal transduction-mediated activation of the aryl hydrocarbon receptor in rat hepatoma H4IIE cells
Backlund M; Johansson I; Mkrtchian S; IngelmanSundberg M
Article: MOLECULAR PHARMACOLOGY. 1997;52(6):1034-1040
A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1997;44(5):439-446
The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Article: MOLECULAR PHARMACOLOGY. 1997;51(3):370-376
Genetic polymorphism of human CYP2E1: Characterization of two variant alleles
Hu Y; Oscarson M; Johansson I; Yue QY; Dahl ML; Tabone M; Arinco S; Albano E; IngelmanSundberg M
Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1997;231(1):227-230
In vitro kinetics of two human CYP1A1 variant enzymes suggested to be associated with interindividual differences in cancer susceptibility
Persson I; Johansson I; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1997;280(1):506-511
Selective centrilobular expression of the aryl hydrocarbon receptor in rat liver
Lindros KO; Oinonen T; Johansson I; IngelmanSundberg M
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1996;51(2):117-122
Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population - Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6
Masimirembwa C; Hasler J; Bertilssons L; Johansson I; Ekberg O; IngelmanSundberg M
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(5):441-447
Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population
Roh HK; Dahl ML; Johansson I; IngelmanSundberg M; Cha YN; Bertilsson L
Article: JOURNAL OF HEPATOLOGY. 1996;25(4):538-546
Hepatotoxicity induced by iron overload and alcohol - Studies on the role of chelatable iron, cytochrome P450 2E1 and lipid peroxidation
Stal P; Johansson I; IngelmanSundberg M; Hagen K; Hultcrantz R
Article: PHARMACOGENETICS AND GENOMICS. 1996;6(4):351-355
PCR-based genotyping for duplicated and deleted CYP2D6 genes
Johansson I; Lundqvist E; Dahl ML; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1996;278(1):441-446
Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles
Aklillu E; Persson I; Bertilsson L; Johansson I; Rodrigues F; IngelmanSundberg M
Article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1995;274(1):516-520
ULTRARAPID HYDROXYLATION OF DEBRISOQUINE IN A SWEDISH POPULATION - ANALYSIS OF THE MOLECULAR-GENETIC BASIS
DAHL ML; JOHANSSON I; BERTILSSON L; INGELMANSUNDBERG M; SJOQVIST F
Article: PHARMACOGENETICS AND GENOMICS. 1995;5(3):159-164
GENETIC-ANALYSIS OF THE CYP2D LOCUS IN RELATION TO DEBRISOQUINE HYDROXYLATION CAPACITY IN KOREAN, JAPANESE AND CHINESE SUBJECTS
DAHL ML; YUE QY; ROH HK; JOHANSSON I; SAWE J; SJOQVIST F; BERTILSSON L
Article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1995;57(6):656-661
PHENOTYPING AND GENOTYPING OF S-MEPHENYTOIN HYDROXYLASE (CYTOCHROME-P450 2C19) IN A SHONA POPULATION OF ZIMBABWE
MASIMIREMBWA C; BERTILSSON L; JOHANSSON I; HASLER JA; INGELMANSUNDBERG M
Article: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY. 1995;39(6):611-620
BIOTRANSFORMATION AND PHARMACOKINETICS OF ETHYLMORPHINE AFTER A SINGLE ORAL DOSE
AASMUNDSTAD TA; XU BQ; JOHANSSON I; RIPEL A; BJORNEBOE A; CHRISTOPHERSEN AS; BODD E; MORLAND J
Article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1995;48(1):35-38
INHIBITORY EFFECTS OF ANTIPARASITIC DRUGS ON CYTOCHROME-P450 2D6
MASIMIREMBWA CM; HASLER JA; JOHANSSON I
Journal article: MOLECULAR PHARMACOLOGY. 1994;46(3):452-459
GENETIC-ANALYSIS OF THE CHINESE CYTOCHROME P4502D LOCUS - CHARACTERIZATION OF VARIANT CYP2D6 GENES PRESENT IN SUBJECTS WITH DIMINISHED CAPACITY FOR DEBRISOQUINE HYDROXYLATION
JOHANSSON I; OSCARSON M; YUE QY; BERTILSSON L; SJOQVIST F; INGELMANSUNDBERG M
Journal article: JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. 1994;269(3):1286-1291
CHLORMETHIAZOLE AS AN EFFICIENT INHIBITOR OF CYTOCHROME-P450 2E1 EXPRESSION IN RAT-LIVER
HU Y; MISHIN V; JOHANSSON I; VONBAHR C; CROSS A; RONIS MJJ; BADGER TM; INGELMANSUNDBERG M
Journal article: EXS. 1994;71:197-207
Genetic polymorphism of cytochrome P450. Functional consequences and possible relationship to disease and alcohol toxicity.
Ingelman-Sundberg M; Johansson I; Persson I; Oscarson M; Hu Y; Bertilsson L; Dahl ML; Sjöqvist F
Journal article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1994;56(4):463-464
CONCORDANCE OF PHENOTYPE AND GENOTYPE FOR CYP2D6 - REPLY
DAHL ML; LLERENA A; HERRAIZ AG; JOHANSSON I
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1993;90(24):11825-11829
INHERITED AMPLIFICATION OF AN ACTIVE GENE IN THE CYTOCHROME-P450 CYP2D LOCUS AS A CAUSE OF ULTRARAPID METABOLISM OF DEBRISOQUINE
JOHANSSON I; LUNDQVIST E; BERTILSSON L; DAHL ML; SJOQVIST F; INGELMANSUNDBERG M
Journal article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1993;54(6):606-611
DEBRISOQUIN AND MEPHENYTOIN HYDROXYLATION PHENOTYPES AND CYP2D6 GENOTYPE IN PATIENTS TREATED WITH NEUROLEPTIC AND ANTIDEPRESSANT AGENTS
LLERENA A; HERRAIZ AG; COBALEDA J; JOHANSSON I; DAHL ML
Journal article: PHARMACOGENETICS AND GENOMICS. 1993;3(6):275-280
GENETIC-POLYMORPHISM OF CYTOCHROME-P450 CYP2D6 IN ZIMBABWEAN POPULATION
MASIMIREMBWA CM; JOHANSSON I; HASLER JA; INGELMANSUNDBERG M
Journal article: ALCOHOL. 1993;10(6):447-452
ETHANOL-INDUCIBLE CYTOCHROME P4502E1 - GENETIC-POLYMORPHISM, REGULATION, AND POSSIBLE ROLE IN THE ETIOLOGY OF ALCOHOL-INDUCED LIVER-DISEASE
INGELMANSUNDBERG M; JOHANSSON I; YIN H; TERELIUS Y; ELIASSON E; CLOT P; ALBANO E
Journal article: PHARMACOGENETICS AND GENOMICS. 1993;3(2):94-100
QUINIDINE INHIBITION OF DEBRISOQUINE S(+)-4-HYDROXYLATIONS AND 7-HYDROXYLATIONS IN CHINESE OF DIFFERENT CYP2D6 GENOTYPES
BERTILSSON L; MEESE CO; YUE QY; DAHL ML; INGELMANSUNDBERG M; JOHANSSON I; SAWE J; EICHELBAUM M
Journal article: FEBS LETTERS. 1993;319(3):207-211
GENETIC-POLYMORPHISM OF CYTOCHROME-P4502E1 IN A SWEDISH POPULATION - RELATIONSHIP TO INCIDENCE OF LUNG-CANCER
PERSSON I; JOHANSSON I; BERGLING H; DAHL ML; SEIDEGARD J; RYLANDER R; RANNUG A; HOGBERG J; SUNDBERG MI
Journal article: LANCET. 1993;341(8836):63
MOLECULAR-BASIS FOR RATIONAL MEGAPRESCRIBING IN ULTRARAPID HYDROXYLATORS OF DEBRISOQUINE
BERTILSSON L; DAHL ML; SJOQVIST F; ABERGWISTEDT A; HUMBLE M; JOHANSSON I; LUNDQVIST E; INGELMANSUNDBERG M
Journal article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1993;44(5):445-450
POLYMORPHIC 2-HYDROXYLATION OF DESIPRAMINE - A POPULATION AND FAMILY STUDY
DAHL ML; ISELIUS L; ALM C; SVENSSON JO; LEE D; JOHANSSON I; INGELMANSUNDBERG M; SJOQVIST F
Journal article: NORDIC JOURNAL OF PSYCHIATRY. 1993;47(sup30):27-31
Molecular basis of drug oxidation polymorphisms
Dahl M-L; Bertilsson L; Ingelman-sundberg M; Johansson I; Lundqvist E; Sjöqvtst F
Journal article: PHARMACOGENETICS AND GENOMICS. 1992;2(6):264-271
GENETIC-POLYMORPHISM OF CYTOCHROMES-P450 - INTERETHNIC DIFFERENCES AND RELATIONSHIP TO INCIDENCE OF LUNG-CANCER
INGELMANSUNDBERG M; JOHANSSON I; PERSSON I; YUE QY; DAHL ML; BERTILSSON L; SJOQVIST F
Journal article: LAKARTIDNINGEN. 1992;89(19):1675-1678
[Genotyping for drug metabolism capacity can give valuable clinical information].
Ingelman-Sundberg M; Johansson I; Dahl ML; Bertilsson L; Yue QY; Sjöqvist F
Journal article: BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY. 1992;70(5):347-352
EFFECTS OF DIETARY-FAT COMPOSITION ON ACTIVITIES OF THE MICROSOMAL ETHANOL OXIDIZING SYSTEM AND ETHANOL-INDUCIBLE CYTOCHROME-P450 (CYP2E1) IN THE LIVER OF RATS CHRONICALLY FED ETHANOL
TAKAHASHI H; JOHANSSON I; FRENCH SW; INGELMANSUNDBERG M
Journal article: FEBS JOURNAL. 1992;204(1):407-412
ZONATION OF CYTOCHROME-P450 ISOZYME EXPRESSION AND INDUCTION IN RAT-LIVER
BUHLER R; LINDROS KO; NORDLING A; JOHANSSON I; INGELMANSUNDBERG M
Journal article: CLINICAL NEUROPHARMACOLOGY. 1992;15 Suppl 1 Pt A:88A-89A
Interethnic differences in drug oxidation. Implications for the utilization of antidepressants and neuroleptics.
Dahl ML; Johansson I; Yue QY; Säwe J; Bertilsson L; Ingelman-Sundberg M; Sjöqvist F
Journal article: CLINICAL PHARMACOLOGY & THERAPEUTICS. 1992;51(1):12-17
ANALYSIS OF THE CYP2D6 GENE IN RELATION TO DEBRISOQUIN AND DESIPRAMINE HYDROXYLATION IN A SWEDISH POPULATION
DAHL ML; JOHANSSON I; PALMERTZ MP; INGELMANSUNDBERG M; SJOQVIST F
Journal article: LAKARTIDNINGEN. 1991;88(28-29):2454-2457
[Drug metabolism is dynamic. It is as adaptable as the immune system].
Ingelman-Sundberg M; Eliasson E; Johansson I
Journal article: FEBS JOURNAL. 1991;198(2):383-389
ACETONE-REGULATED SYNTHESIS AND DEGRADATION OF CYTOCHROME-P4502E2 AND CYTOCHROME-P4502B1 IN RAT-LIVER
RONIS MJJ; JOHANSSON I; HULTENBY K; LAGERCRANTZ J; GLAUMANN H; INGELMANSUNDBERG M
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1991;174(1):37-42
HORMONE CONTROLLED PHOSPHORYLATION AND DEGRADATION OF CYP2B1 AND CYP2E1 IN ISOLATED RAT HEPATOCYTES
JOHANSSON I; ELIASSON E; INGELMANSUNDBERG M
Journal article: EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY. 1991;40(6):553-556
GENETIC-ANALYSIS OF THE INTERETHNIC DIFFERENCE BETWEEN CHINESE AND CAUCASIANS IN THE POLYMORPHIC METABOLISM OF DEBRISOQUINE AND CODEINE
JOHANSSON I; YUE QY; DAHL ML; HEIM M; SAWE J; BERTILSSON L; MEYER UA; SJOQVIST F; INGELMANSUNDBERG M
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1990;173(1):331-338
TRANSCRIPTIONAL CONTROL OF CYP2E1 IN THE PERIVENOUS LIVER REGION AND DURING STARVATION
JOHANSSON I; LINDROS KO; ERIKSSON H; INGELMANSUNDBERG M
Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1990;87(8):3225-3229
SUBSTRATE-REGULATED, HORMONE-REGULATED, AND CAMP-REGULATED CYTOCHROME P450 DEGRADATION
ELIASSON E; JOHANSSON I; INGELMANSUNDBERG M
Journal article: LANCET. 1989;2(8678-8679):1534-1535
Debrisoquine phenotype and genotype in Chinese.
Caporaso N; Pickle L
Journal article: LANCET. 1989;2(8667):870
DISASSOCIATION BETWEEN DEBRISOQUINE HYDROXYLATION PHENOTYPE AND GENOTYPE AMONG CHINESE
YUE QY; BERTILSSON L; DAHLPUUSTINEN ML; SAWE J; SJOQVIST F; JOHANSSON I; INGELMANSUNDBERG M
Journal article: LANCET. 1989;2(8678-9):1534
DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE - REPLY
YUE QY; BERTILSSON L; DAHLPUUSTINEN ML; SAWE J; SJOQVIST F; JOHANSSON I; INGELMANSUNDBERG M
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1988;157(1):55-60
CENTRILOBULAR EXPRESSION OF ETHANOL-INDUCIBLE CYTOCHROME-P-450 (IIE1) IN RAT-LIVER
INGELMANSUNDBERG M; JOHANSSON I; PENTTILA KE; GLAUMANN H; LINDROS KO
Journal article: CANCER RESEARCH. 1988;48(19):5387-5390
BENZENE METABOLISM BY ETHANOL-INDUCIBLE, ACETONE-INDUCIBLE, AND BENZENE-INDUCIBLE CYTOCHROME-P-450 (IIE1) IN RAT AND RABBIT LIVER-MICROSOMES
JOHANSSON I; INGELMANSUNDBERG M
Journal article: BIOCHEMISTRY. 1988;27(6):1925-1934
ETHANOL-INDUCIBLE, FASTING-INDUCIBLE, AND ACETONE-INDUCIBLE CYTOCHROMES-P-450 IN RAT-LIVER - REGULATION AND CHARACTERISTICS OF ENZYMES BELONGING TO THE IIB-GENE AND IIE-GENE SUBFAMILIES
JOHANSSON I; EKSTROM G; SCHOLTE B; PUZYCKI D; JORNVALL H; INGELMANSUNDBERG M
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1988;150(1):436-443
LIGAND-DEPENDENT MAINTENANCE OF ETHANOL-INDUCIBLE CYTOCHROME-P-450 IN PRIMARY RAT HEPATOCYTE CELL-CULTURES
ELIASSON E; JOHANSSON I; INGELMANSUNDBERG M
Journal article: FEBS LETTERS. 1986;196(1):59-64
HYDROXYLATION OF ACETONE BY ETHANOL-INDUCED AND ACETONE-INDUCIBLE CYTOCHROME-P-450 IN LIVER-MICROSOMES AND RECONSTITUTED MEMBRANES
JOHANSSON I; ELIASSON E; NORSTEN C; INGELMANSUNDBERG M
Journal article: FEBS LETTERS. 1985;183(2):265-269
CARBON TETRACHLORIDE-INDUCED LIPID-PEROXIDATION DEPENDENT ON AN ETHANOL-INDUCIBLE FORM OF RABBIT LIVER MICROSOMAL CYTOCHROME-P-450
JOHANSSON I; INGELMANSUNDBERG M
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1984;259(10):6447-6458
MECHANISMS OF HYDROXYL RADICAL FORMATION AND ETHANOL OXIDATION BY ETHANOL-INDUCIBLE AND OTHER FORMS OF RABBIT LIVER MICROSOMAL CYTOCHROMES-P-450
INGELMANSUNDBERG M; JOHANSSON I
Journal article: ACTA CHEMICA SCANDINAVICA. 1984;38(10):845-851
ELECTRON FLOW AND COMPLEX-FORMATION DURING CYTOCHROME-P-450-CATALYZED HYDROXYLATION REACTIONS IN RECONSTITUTED MEMBRANE-VESICLES
INGELMANSUNDBERG M; JOHANSSON I
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1983;258(12):7311-7316
HYDROXYL RADICAL-MEDIATED, CYTOCHROME-P-450-DEPENDENT METABOLIC-ACTIVATION OF BENZENE IN MICROSOMES AND RECONSTITUTED ENZYME-SYSTEMS FROM RABBIT LIVER
JOHANSSON I; INGELMANSUNDBERG M
Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 1981;256(12):6321-6326
THE MECHANISM OF CYTOCHROME-P-450-DEPENDENT OXIDATION OF ETHANOL IN RECONSTITUTED MEMBRANE-VESICLES
INGELMANSUNDBERG M; JOHANSSON I
Journal article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1980;97(2):582-589
CYTOCHROME-B5 AS ELECTRON-DONOR TO RABBIT LIVER CYTOCHROME-P-450LM2 IN RECONSTITUTED PHOSPHOLIPID-VESICLES
INGELMANSUNDBERG M; JOHANSSON I
Journal article: BIOCHEMISTRY. 1980;19(17):4004-4011
CATALYTIC PROPERTIES OF PURIFIED FORMS OF RABBIT LIVER MICROSOMAL CYTOCHROME-P-450 IN RECONSTITUTED PHOSPHOLIPID-VESICLES
INGELMANSUNDBERG M; JOHANSSON I
Journal article: ACTA BIOLOGICA ET MEDICA GERMANICA. 1979;38(2-3):379-388
CATALYTIC PROPERTIES OF THE LIVER MICROSOMAL HYDROXYLASE SYSTEM IN RECONSTITUTED PHOSPHOLIPID-VESICLES
INGELMANSUNDBERG M; JOHANSSON I; HANSSON A
Show more

All other publications

Letter: CLINICAL PHARMACOLOGY & THERAPEUTICS. 2022;112(6):1155
Response to Rowland et al. and Achour et al.
Pridgeon CS; Johansson I; Ingelman-Sundberg M
Preprint: BIORXIV. 2020
A unifying model to predict variable drug response for personalised medicine
van der Lee M; Allard WG; Vossen RHAM; Baak-Pablo RF; Menafra R; Deiman BALM; Deenen MJ; Neven P; Johansson I; Gastaldello S; Ingelman-Sundberg M; Guchelaar H-J; Swen JJ; Anvar SY
Review: DRUG METABOLISM REVIEWS. 2016;48(3):369-378
The CYP2W1 enzyme: regulation, properties and activation of prodrugs
Guo J; Johansson I; Mkrtchian S; Ingelman-Sundberg M
Conference publication: TOXICOLOGY LETTERS. 2015;238(2):S31
Prediction of long term toxic effects by genome based network models
Terfloth L; Bucher J; Klein S; Tascher G; Johansson I; Magioni S; Bertile F; Ingelman-Sundberg M; van Dorsselaer A; Benfenati E; Noor F; Heinzle E; Mauch K
Conference publication: TOXICOLOGY LETTERS. 2015;238(2):S30
Toxicoproteomics applied to in vitro investigation of liver toxicity using HepaRG cells
Bertile F; Tascher G; Mueller D; Klein S; Fredricksson L; Johansson I; Shevchenko V; Chesne C; Ingelmann-Sundberg M; Heinzle E; Noor F; Van Dorsselaer A
Conference publication: EUROPEAN JOURNAL OF CANCER. 2014;50:95
Progress in drugging CYP1A1, 1B1 and CYP2W1 overexpressed in cancer
Pors K; Le Morvan V; Travica S; Shnyder SD; Sutherland M; Sheldrake HM; Searcey M; Johansson I; Mkrtchian S; Loadman PM; Robert J; Ingelman-Sundberg M; Patterson LH
Conference publication: CANCER RESEARCH. 2014;74(19):1779
CYP2W1 as a novel therapeutic target in colon cancer
Pors K; Loadman PM; Travica S; Shnyder SD; Sutherland M; Sheldrake H; Searcey M; Johansson I; Mkrtchian S; Ingelman-Sundberg M; Patterson LH
Conference publication: DRUG METABOLISM REVIEWS. 2009;41:55
Directed Differentiation of Human Embryonic Stem Cells into Hepatocytes for In Vitro Applications
Edsbagge J; Kuppers-Munther B; Lindqvist J; Strom C; Brolen G; Heins N; Rehnstrom M; Athley L; Eriksson G; Jensen J; Ek M; Sivertsson L; Darnell M; Andersson TB; Johansson I; Ingelman-Sundberg M; Bjorquist P
Other: DRUG NEWS AND PERSPECTIVES. 2008;21(9):518-528
Current research in drug metabolism, drug transport and drug development.
Johansson I; Ingelman-Sundberg M
Conference publication: DRUG METABOLISM REVIEWS. 2008;40:98-99
HEPATOCYTE-LIKE CELLS DERIVED FROM HUMAN EMBRYONIC STEM CELLS VIA DEFINITIVE ENDODERM DISPLAY DRUG METABOLISING ACTIVITY
Kuppers-Munther B; Ek M; Edsbagge J; Heins N; Brolen G; Rehnstrom M; Athley E; Darnell M; Andersson TB; Johansson I; Ingelman-Sundberg M; Bjorquist P
Conference publication: DRUG METABOLISM REVIEWS. 2005;37:48-49
Identification of stearoyl coa desaturase as the enzyme responsible for the reduction of ximelagatran/n-hydroxymelagatran and benzamidoxime in adipocytes
Johansson I; Thelin A; Hofmann Y; Andersson S; Nordling A; Li QX; Carlsson SC; Andersson TB; Ingelman-Sundberg M
Conference publication: DRUG METABOLISM REVIEWS. 2005;37:27-28
Characterization of the rat and human enzyme systems active in the reduction of N-hydroxymelagatran and benzamidoxime
Andersson S; Hofmann Y; Nordling A; Li XQ; Nivelius S; Andersson TB; Ingelman-Sundberg M; Johansson I
Other: DRUG NEWS AND PERSPECTIVES. 2004;17(9):594-605
New approaches and applications in chemical biology.
Gomez A; Ingelman-Sundberg M; Johansson I; Karlgren M; Rodriguez-Antona C; Sim SC
Published conference paper: DRUG METABOLISM AND DISPOSITION. 2004;32(5):484-489
The impact of CYP2C9 genetics and oral contraceptives on cytochrome P4502C9 phenotype
Sandberg M; Johansson I; Christensen M; Rane A; Eliasson E
Conference publication: DRUG METABOLISM REVIEWS. 2004;36:320
Differentiation of human hepatoma cells during confluence as revealed by gene expression profiling
Butura A; Johansson I; Nilsson K; Wärngård L; Ingelman-Sundberg M; Schuppe-Koistinen I
Conference publication: DRUG METABOLISM REVIEWS. 2004;36:101
Reduction of the amidoximes: Preliminary characterization of the enzyme system reducing the hydroxyamidine function in ximelagatran
Andersson TB; Andersson S; Li XQ; Johansson I; Carlsson S; Ingelman-Sundberg M
Conference publication: DRUG METABOLISM REVIEWS. 2003;35:65
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (Malarone) when taken as chemoprophylaxis
Mita TM; Ashton M; Lindegardh N; Bergqvist Y; Nivelius S; Johansson I; Bjorkman A
Conference publication: DRUG METABOLISM REVIEWS. 2003;35:43
Time-dependent pharmacokinetics and drug metabolism of atovaquone plus proguanil (malarone) when taken as chemoprophylaxis
Mita TM; Ashton M; Lindegardh N; Bergqvist Y; Nivelius S; Johansson I; Bjorkman A
Conference publication: DRUG METABOLISM REVIEWS. 2003;35:130
Identification and characterisation of novel SNPS in the 5′-flanking region of the CYP2C9 gene
Sandberg M; Bloethner S; Malmebo S; Rane A; Johansson I; Eliasson E
Published conference paper: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 2001;281(5):1349-1355
Cloning and tissue distribution of a novel human cytochrome P450 of the CYP3A subfamily, CYP3A43
Westlind A; Malmebo S; Johansson I; Otter C; Andersson TB; Ingelman-Sundberg M; Oscarson M
Corrigendum: PHARMACOGENETICS AND GENOMICS. 2001;11(8):743
Characterization of the CYP2D6*29 allele commonly present in a black Tanzanian population causing reduced catalytic activity (vol 11, pg 417, 2001)
Wennerholm A; Johansson I; Hidestrand M; Bertilsson L; Gustafsson LL; IngelmanSundberg M
Conference publication: HEPATOLOGY. 1992;16(4):A232
IRON, ALCOHOL, FREE-RADICAL PRODUCTION AND CELL-DAMAGE
HULTCRANTZ R; STAL P; JOHANSSON I; INGELMANSUNDBERG M
Conference publication: HEPATOLOGY. 1990;12(4):979
EFFECT OF THE TYPE OF DIETARY-FAT AND ETHANOL ON MEOS, ALCOHOL INDUCIBLE CYTOCHROME-P450 AND PARA-NITROPHENOL HYDROXYLASE-ACTIVITY
FRENCH SW; TAKAHASHI H; JOHANSSON I; INGELMANSUNDBERG M
Conference publication: ALCOHOL AND ALCOHOLISM. 1987;22(3):A15
ETHANOL, FASTING AND ACETONE-INDUCIBLE CYTOCHROMES-P-450 IN RAT-LIVER
JOHANSSON I; INGELMANSUNDBERG M
Conference publication: ALCOHOL AND ALCOHOLISM. 1987;22(3):A4
LIPID-PEROXIDATION DEPENDENT ON ETHANOL-INDUCIBLE CYTOCHROME-P-450 FROM RAT-LIVER
INGELMANSUNDBERG M; EKSTROM G; TINDBERG N; JOHANSSON I
Book chapter: MICROSOMES, DRUG OXIDATIONS AND CHEMICAL CARCINOGENESIS. 1980;p. 513-516
PROPERTIES OF PURIFIED FORMS OF RABBIT LIVER MICROSOMAL CYTOCHROME P-450 AND NADPH-CYTOCHROME P-450 REDUCTASE IN RECONSTITUTED PHOSPHOLIPID VESICLES11Supported by Magnus Bergvalls Stiftelse, Harald och Greta Jeanssons Stiftelse and the Swedish Cancer Society (grant no 251).
Ingelman–Sundberg M; Glaumann H; Johansson I
Show more

Grants

New human in vitro systems for better prediction of drug induced hepatotoxicity
Swedish Research Council
1 January 2009 - 31 December 2011

Articles

All other publications

Grants

News from KI

Events from KI